William Blair Dumps $21 Million of Healthcare Platform Doximity Stock

William Blair reduced its Doximity (DOCS) stake by 372,184 shares in Q4 2025 (SEC filing dated Feb. 9, 2026), an estimated $20.89 million transaction using quarterly average pricing; the fund held 5,456,985 shares at quarter-end valued at $241.64 million, representing 0.67% of reportable AUM. The quarter-end value of the position fell by $184.77 million reflecting both the sale and a steep share-price decline (DOCS at $27.73 on Feb. 6, 2026, down ~66% Y/Y), while the company reports TTM revenue of $637.78 million and net income of $239.40 million and is planning broader AI monetization in 2026. The sale represents roughly 15% of William Blair’s shares of DOCS and is notable for positioning and sentiment but is unlikely to be materially market-moving on its own.

Analysis

Market structure: William Blair’s modest 15% trim of its DOCS stake (372,184 shares, ~$21m) is signal-lite versus the stock’s 66% Y/Y collapse and 17x FCF valuation; primary beneficiaries are value-seeking long-term healthcare-platform buyers if pharma ad budgets resume, while short-term holders and momentum funds are hurt by headline-driven outflows. Competitive dynamics favor Doximity vs generalist ad channels because of 85% physician reach, so pricing power for targeted pharma ads could recover quickly once MFN-related spend normalizes; a meaningful rebound requires sustained >10% pharma bookings growth over two consecutive quarters. Supply/demand: current share supply is elevated via distress selling and de-risking by active managers; absent new equity issuance, supply should abate, so marginal demand (pharma booking recovery + AI monetization) can drive outsized returns. Cross-asset: limited direct bond/FX impact, but higher idiosyncratic equity vol raises option implied vol; hedge demand may lift healthcare-tech vols and modestly divert flows from growth mega-caps (NVDA, MSFT) into beaten-down specialty tech names.

Risk assessment: Tail risks include pharma regulatory clampdowns on targeted advertising or a second wave of MFN-like contract shifts that could sustain bookings below 5% for multiple quarters, and operational execution risk around 2026 AI monetization. Time horizons: days-weeks expect headline-driven volatility and 10–25% intraday moves on earnings updates; 3–12 months hinge on pharma bookings trends and early AI revenue proof points; 12–36 months depend on sustained FCF growth and multiple expansion. Hidden dependencies: Doximity’s monetization depends on pharma CTOs restoring spend and on salesforce execution—both can lag board commentary by 1–3 quarters. Key catalysts: monthly pharma bookings datapoints, Q1–Q2 2026 bookings/revenue, and first paid AI-product revenue reports (target: material contribution by Q4 2026).

Key Decisions for Investors

• Establish a staggered 2–3% long position in Doximity (DOCS): 25% at market (~$27.7), 50% if price < $25, final 25% if price < $20. Set hard stop-loss at -25% from entry (~$20.75) and target +50% upside within 12–18 months (~$41) predicated on multiple re-rating to ~25x FCF if bookings recover.
• Express asymmetric upside via options: buy a 12-month call spread (buy Jan 2027 DOCS $25 call, sell Jan 2027 DOCS $45 call). Size premium risk to no more than 1% of portfolio; this captures recovery + AI-monetization upside while capping downside to premium paid.
• Hedge macro beta: pair the DOCS long with a short S&P 500 futures (ES) position sized ~50% of DOCS delta exposure for 3–6 months to isolate idiosyncratic recovery. Remove hedge after two consecutive quarters of >10% pharma bookings growth or upon Q3 2026 AI revenue confirmation.
• Risk-trigger sell rules: reduce DOCS to <0.5% portfolio if (a) two consecutive quarters of pharma bookings growth <5%, or (b) company guidance cut for two straight quarters, or (c) regulatory action limiting targeted pharma advertising within 90 days. Re-enter only after one quarter of positive bookings revision and confirming AI monetization traction.